Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Livmarli
Pharma
Mirum keeps momentum with ph. 3 win for Livmarli
Mirum boasts another win for its anti-itch pipeline with Livmarli phase 3 results.
Donavyn Coffey
Oct 12, 2026 11:18am
Ipsen's liver disease drug Bylvay fails biliary atresia trial
Jul 24, 2026 11:00am
Mirum gets 2nd indication for blockbuster hopeful Livmarli
Mar 13, 2024 6:20pm
Mirum ponies up $445M for 2 Travere liver disease drugs
Jul 18, 2023 8:00am
Ipsen pays $952M to acquire Albireo and liver disease med Bylvay
Jan 9, 2023 10:05am
Mirum gets a leg up on Albireo in pediatric liver disease
Oct 24, 2022 3:11pm
